Skip to main content
SpringerLink
Log in

Anti-fibrotic effects of curcumin and some of its analogues in the heart

  • Published:
Heart Failure Reviews Aims and scope Submit manuscript

Abstract

Cardiac fibrosis stems from the changes in the expression of fibrotic genes in cardiac fibroblasts (CFs) in response to the tissue damage induced by various cardiovascular diseases (CVDs) leading to their transformation into active myofibroblasts, which produce high amounts of extracellular matrix (ECM) proteins leading, in turn, to excessive deposition of ECM in cardiac tissue. The excessive accumulation of ECM elements causes heart stiffness, tissue scarring, electrical conduction disruption and finally cardiac dysfunction and heart failure. Curcumin (Cur; also known as diferuloylmethane) is a polyphenol compound extracted from rhizomes of Curcuma longa with an influence on an extensive spectrum of biological phenomena including cell proliferation, differentiation, inflammation, pathogenesis, chemoprevention, apoptosis, angiogenesis and cardiac pathological changes. Cumulative evidence has suggested a beneficial role for Cur in improving disrupted cardiac function developed by cardiac fibrosis by establishing a balance between degradation and synthesis of ECM components. There are various molecular mechanisms contributing to the development of cardiac fibrosis. We presented a review of Cur effects on cardiac fibrosis and the discovered underlying mechanisms by them Cur interact to establish its cardio-protective effects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Grimaldi V, De Pascale MR, Zullo A, Soricelli A, Infante T, Mancini FP, Napoli C (2017) Evidence of epigenetic tags in cardiac fibrosis. J Cardiol 69(2):401–408

    PubMed  Google Scholar 

  2. Russo I, Frangogiannis NG (2016) Diabetes-associated cardiac fibrosis: cellular effectors, molecular mechanisms and therapeutic opportunities. J Mol Cell Cardiol 90:84–93. https://doi.org/10.1016/j.yjmcc.2015.12.011

    Article  CAS  PubMed  Google Scholar 

  3. Tao H, Shi K-H, Yang J-J, Huang C, Liu L-P, Li J (2013) Epigenetic regulation of cardiac fibrosis. Cell Signal 25(9):1932–1938

    CAS  PubMed  Google Scholar 

  4. Wang NP, Wang ZF, Tootle S, Philip T, Zhao ZQ (2012) Curcumin promotes cardiac repair and ameliorates cardiac dysfunction following myocardial infarction. Br J Pharmacol 167(7):1550–1562

    CAS  PubMed  PubMed Central  Google Scholar 

  5. van Putten S, Shafieyan Y, Hinz B (2016) Mechanical control of cardiac myofibroblasts. J Mol Cell Cardiol 93:133–142. https://doi.org/10.1016/j.yjmcc.2015.11.025

    Article  CAS  PubMed  Google Scholar 

  6. Creemers EE, van Rooij E (2016) Function and therapeutic potential of noncoding RNAs in cardiac fibrosis. Circ Res 118(1):108–118

    CAS  PubMed  Google Scholar 

  7. Micheletti R, Plaisance I, Abraham BJ, Sarre A, Ting C-C, Alexanian M, Maric D, Maison D, Nemir M, Young RA (2017) The long noncoding RNA Wisper controls cardiac fibrosis and remodeling. Sci Transl Med 9(395):eaai9118

    PubMed  PubMed Central  Google Scholar 

  8. Xiao J, Sheng X, Zhang X, Guo M, Ji X (2016) Curcumin protects against myocardial infarction-induced cardiac fibrosis via SIRT1 activation in vivo and in vitro. Drug design, development and therapy 10:1267

    CAS  PubMed  PubMed Central  Google Scholar 

  9. Kunnumakkara AB, Bordoloi D, Padmavathi G, Monisha J, Roy NK, Prasad S, Aggarwal BB (2017) Curcumin, the golden nutraceutical: multitargeting for multiple chronic diseases. Br J Pharmacol 174(11):1325–1348

    CAS  PubMed  Google Scholar 

  10. Panahi Y, Kianpour P, Mohtashami R, Jafari R, Simental-Mendía LE, Sahebkar A (2017) Efficacy and Safety of Phytosomal Curcumin in Non-Alcoholic Fatty Liver Disease: A Randomized Controlled Trial. Drug Res 67(4):244–251. https://doi.org/10.1055/s-0043-100019

  11. Rezaee R, Momtazi AA, Monemi A, Sahebkar A (2017) Curcumin: A potentially powerful tool to reverse cisplatin-induced toxicity. Pharmacol Res 117:218–227. https://doi.org/10.1016/j.phrs.2016.12.037

  12. Karimian MS, Pirro M, Majeed M, Sahebkar A (2017) Curcumin as a natural regulator of monocyte chemoattractant protein-1. Cytokine Growth F R 33:55–63. https://doi.org/10.1016/j.cytogfr.2016.10.001

    Article  CAS  Google Scholar 

  13. Sahebkar A, Cicero AFG, Simental-Mendia LE, Aggarwal BB, Gupta SC (2016) Curcumin downregulates human tumor necrosis factor-alpha levels: a systematic review and meta-analysis ofrandomized controlled trials. Pharmacol Res 107:234–242. https://doi.org/10.1016/j.phrs.2016.03.026

    Article  CAS  PubMed  Google Scholar 

  14. Wongcharoen W, Phrommintikul A (2009) The protective role of curcumin in cardiovascular diseases. Int J Cardiol 133(2):145–151

    PubMed  Google Scholar 

  15. Fang G, Chen S, Huang Q, Chen L, Liao D (2018) Curcumin suppresses cardiac fibroblasts activities by regulating the proliferation and cell cycle via the inhibition of the p38 MAPK/ERK signaling pathway. Mol Med Rep 18(2):1433–1438

    CAS  PubMed  PubMed Central  Google Scholar 

  16. Meng Z, Yu X-h, Chen J, Li L, Li S (2014) Curcumin attenuates cardiac fibrosis in spontaneously hypertensive rats through PPAR-γ activation. Acta Pharmacol Sin 35(10):1247

    CAS  PubMed  PubMed Central  Google Scholar 

  17. Leask A (2010) Potential therapeutic targets for cardiac fibrosis: TGFβ, angiotensin, endothelin, CCN2, and PDGF, partners in fibroblast activation. Circ Res 106(11):1675–1680

    CAS  PubMed  Google Scholar 

  18. Valente AJ, Sakamuri SS, Siddesha JM, Yoshida T, Gardner JD, Prabhu R, Siebenlist U, Chandrasekar B (2013) TRAF3IP2 mediates interleukin-18-induced cardiac fibroblast migration and differentiation. Cell Signal 25(11):2176–2184

    CAS  PubMed  PubMed Central  Google Scholar 

  19. Zhao T, Zhao W, Chen Y, Li VS, Meng W, Sun Y (2013) Platelet-derived growth factor-D promotes fibrogenesis of cardiac fibroblasts. Am J Phys Heart Circ Phys 304(12):H1719–H1726

    CAS  Google Scholar 

  20. Shimosawa T (2013) Salt, the renin–angiotensin–aldosterone system and resistant hypertension. Hypertens Res 36(8):657

    CAS  PubMed  Google Scholar 

  21. de Cavanagh EM, Ferder M, Inserra F, Ferder L (2009) Angiotensin II, mitochondria, cytoskeletal, and extracellular matrix connections: an integrating viewpoint. Am J Phys Heart Circ Phys 296(3):H550–H558

    Google Scholar 

  22. Siddesha JM, Valente AJ, Sakamuri SS, Yoshida T, Gardner JD, Somanna N, Takahashi C, Noda M, Chandrasekar B (2013) Angiotensin II stimulates cardiac fibroblast migration via the differential regulation of matrixins and RECK. J Mol Cell Cardiol 65:9–18. https://doi.org/10.1016/j.yjmcc.2013.09.015

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Crowley MJ, Powers BJ, Myers ER, McBroom AJ, Sanders GD (2012) Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treatment of ischemic heart disease: future research needs prioritization. Am Heart J 163(5):777–782 e778

    CAS  PubMed  Google Scholar 

  24. Ghosh AK, Vaughan DE (2012) PAI-1 in tissue fibrosis. J Cell Physiol 227(2):493–507

    CAS  PubMed  PubMed Central  Google Scholar 

  25. Weisberg AD, Albornoz F, Griffin JP, Crandall DL, Elokdah H, Fogo AB, Vaughan DE, Brown NJ (2005) Pharmacological inhibition and genetic deficiency of plasminogen activator inhibitor-1 attenuates angiotensin II/salt-induced aortic remodeling. Arterioscler Thromb Vasc Biol 25(2):365–371

    CAS  PubMed  Google Scholar 

  26. Khan R, Sheppard R (2006) Fibrosis in heart disease: understanding the role of transforming growth factor-β1 in cardiomyopathy, valvular disease and arrhythmia. Immunology 118(1):10–24

    CAS  PubMed  PubMed Central  Google Scholar 

  27. Hein S, Arnon E, Kostin S, Schönburg M, Elsässer A, Polyakova V, Bauer EP, Klövekorn W-P, Schaper J (2003) Progression from compensated hypertrophy to failure in the pressure-overloaded human heart: structural deterioration and compensatory mechanisms. Circulation 107(7):984–991

    PubMed  Google Scholar 

  28. Ghosh AK, Varga J (2007) The transcriptional coactivator and acetyltransferase p300 in fibroblast biology and fibrosis. J Cell Physiol 213(3):663–671

    CAS  PubMed  Google Scholar 

  29. Daniels A, Van Bilsen M, Goldschmeding R, Van Der Vusse G, Van Nieuwenhoven F (2009) Connective tissue growth factor and cardiac fibrosis. Acta Physiol 195(3):321–338

    CAS  Google Scholar 

  30. Gao D-F, Niu X-L, Hao G-H, Peng N, Wei J, Ning N, Wang N-P (2007) Rosiglitazone inhibits angiotensin II-induced CTGF expression in vascular smooth muscle cells––role of PPAR-γ in vascular fibrosis. Biochem Pharmacol 73(2):185–197

    CAS  PubMed  Google Scholar 

  31. Derosa G, Maffioli P (2012) Peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists on glycemic control, lipid profile and cardiovascular risk. Curr Mol Pharmacol 5(2):272–281

    CAS  PubMed  Google Scholar 

  32. Ahmadian M, Suh JM, Hah N, Liddle C, Atkins AR, Downes M, Evans RM (2013) PPARγ signaling and metabolism: the good, the bad and the future. Nat Med 19(5):557

    CAS  PubMed  Google Scholar 

  33. Wei W-Y, Zhang N, Li L-L, Ma Z-G, Xu M, Yuan Y-P, Deng W, Tang Q-Z (2018) Pioglitazone alleviates cardiac fibrosis and inhibits endothelial to mesenchymal transition induced by pressure overload. Cell Physiol Biochem 45(1):26–36

    CAS  PubMed  Google Scholar 

  34. Singh RM, Cummings E, Pantos C, Singh J (2017) Protein kinase C and cardiac dysfunction: a review. Heart Fail Rev 22(6):843–859

    CAS  PubMed  PubMed Central  Google Scholar 

  35. Huang K-P (1989) The mechanism of protein kinase C activation. Trends Neurosci 12(11):425–432

    CAS  PubMed  Google Scholar 

  36. Singh RK, Kumar S, Gautam PK, Tomar MS, Verma PK, Singh SP, Acharya A (2017) Protein kinase C-α and the regulation of diverse cell responses. Biomolecular concepts 8(3–4):143–153

    CAS  PubMed  Google Scholar 

  37. Roberts AC, Porter KE (2013) Cellular and molecular mechanisms of endothelial dysfunction in diabetes. Diabetes and Vascular Disease Research 10(6):472–482

    PubMed  Google Scholar 

  38. Davis J, Molkentin JD (2014) Myofibroblasts: trust your heart and let fate decide. J Mol Cell Cardiol 70:9–18

    CAS  PubMed  Google Scholar 

  39. Cicero AFG, Colletti A, Bajraktari G, Descamps O, Djuric DM, Ezhov M, Fras Z, Katsiki N, Langlois M, Latkovskis G, Panagiotakos DB, Paragh G, Mikhailidis DP, Mitchenko O, Paulweber B, Pella D, Pitsavos C, Reiner Z, Ray KK, Rizzo M, Sahebkar A, Serban MC, Sperling LS, Toth PP, Vinereanu D, Vrablík M, Wong ND, Banach M (2017) Lipid-lowering nutraceuticals in clinical practice: position paper from an international lipid expert panel. Nutr Rev 75(9):731–767. https://doi.org/10.1093/nutrit/nux047

    Article  PubMed  Google Scholar 

  40. Panahi Y, Khalili N, Sahebi E, Namazi S, Karimian MS, Majeed M, Sahebkar A (2017) Antioxidant effects of curcuminoids in patients with type 2 diabetes mellitus: a randomized controlled trial. Inflammopharmacology 25(1):25–31. https://doi.org/10.1007/s10787-016-0301-4

    Article  CAS  PubMed  Google Scholar 

  41. Sahebkar A, Cicero AFG, Simental-Mendía LE, Aggarwal BB, Gupta SC (2016) Curcumin downregulates human tumor necrosis factor-α levels: a systematic review and meta-analysis ofrandomized controlled trials. Pharmacol Res 107:234–242. https://doi.org/10.1016/j.phrs.2016.03.026

    Article  CAS  PubMed  Google Scholar 

  42. Liu W, Zhai Y, Heng X, Che FY, Chen W, Sun D, Zhai G (2016) Oral bioavailability of curcumin: problems and advancements. J Drug Target 24(8):694–702

    CAS  PubMed  Google Scholar 

  43. Hagl S, Kocher A, Schiborr C, Kolesova N, Frank J, Eckert GP (2015) Curcumin micelles improve mitochondrial function in neuronal PC12 cells and brains of NMRI mice - impact on bioavailability. Neurochem Int 89:234–242. https://doi.org/10.1016/j.neuint.2015.07.026

    Article  CAS  PubMed  Google Scholar 

  44. Sandhir R, Yadav A, Mehrotra A, Sunkaria A, Singh A, Sharma S (2014) Curcumin nanoparticles attenuate neurochemical and neurobehavioral deficits in experimental model of Huntington's disease. NeuroMolecular Med 16(1):106–118. https://doi.org/10.1007/s12017-013-8261-y

    Article  CAS  PubMed  Google Scholar 

  45. Chojnacki JE, Liu K, Yan X, Toldo S, Selden T, Estrada M, Rodríguez-Franco MI, Halquist MS, Ye D, Zhang S (2014) Discovery of 5-(4-hydroxyphenyl)-3-oxo-pentanoic acid [2-(5-methoxy-1H-indol-3-yl)-ethyl]-amide as a neuroprotectant for Alzheimer's disease by hybridization of curcumin and melatonin. ACS Chem Neurosci 5(8):690–699. https://doi.org/10.1021/cn500081s

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Chang CZ, Wu SC, Lin CL, Kwan AL (2015) Curcumin, encapsulated in nano-sized PLGA, down-regulates nuclear factor kappaB (p65) and subarachnoid hemorrhage induced early brain injury in a rat model. Brain Res 1608:215–224. https://doi.org/10.1016/j.brainres.2015.02.039

    Article  CAS  PubMed  Google Scholar 

  47. Jayaraj RL, Tamilselvam K, Manivasagam T, Elangovan N (2013) Neuroprotective effect of CNB-001, a novel pyrazole derivative of curcumin on biochemical and apoptotic markers against rotenone-induced SK-N-SH cellular model of Parkinson's disease. Journal of molecular neuroscience : MN 51(3):863–870. https://doi.org/10.1007/s12031-013-0075-8

    Article  CAS  PubMed  Google Scholar 

  48. Mythri RB, Harish G, Dubey SK, Misra K, Bharath MM (2011) Glutamoyl diester of the dietary polyphenol curcumin offers improved protection against peroxynitrite-mediated nitrosative stress and damage of brain mitochondria in vitro: implications for Parkinson's disease. Mol Cell Biochem 347(1–2):135–143. https://doi.org/10.1007/s11010-010-0621-4

    Article  CAS  PubMed  Google Scholar 

  49. Pan Y, Wang Y, Zhao Y, Peng K, Li W, Wang Y, Zhang J, Zhou S, Liu Q, Li X (2014) Inhibition of JNK phosphorylation by a novel curcumin analog prevents high glucose–induced inflammation and apoptosis in cardiomyocytes and the development of diabetic cardiomyopathy. Diabetes 63(10):3497–3511

    CAS  PubMed  Google Scholar 

  50. Chen HJ, Yang X, Lu KQ, Lu C, Zhao YJ, Zheng SQ, Li JL, Huang ZJ, Huang Y, Zhang YL, Liang G (2017) Inhibition of high glucose-induced inflammation and fibrosis by a novel curcumin derivative prevents renal and heart injury in diabetic mice. Toxicol Lett 278:48–58. https://doi.org/10.1016/j.toxlet.2017.07.212

    Article  CAS  PubMed  Google Scholar 

  51. Li KF, Zhai MG, Jiang LQ, Song F, Zhang B, Li J, Li H, Li BY, Xia L, Xu L, Cao Y, He MS, Zhu HZ, Zhang LY, Liang HL, Jin ZX, Duan WX, Wang SW (2019) Tetrahydrocurcumin ameliorates diabetic cardiomyopathy by attenuating high glucose-induced oxidative stress and fibrosis via activating the SIRT1 pathway. Oxidative Med Cell Longev 2019:Artn 6746907. https://doi.org/10.1155/2019/6746907

    Article  CAS  Google Scholar 

  52. Tang Y, Bao M, Yang B, Zhang Y, Zhang B, Zhou Q, Chen J, Huang C (2009) Curcumin attenuates left ventricular dysfunction and remodeling in rabbits with chronic heart failure. Zhonghua xin xue guan bing za zhi 37(3):262–267

    CAS  PubMed  Google Scholar 

  53. Nakayama N, Nakamura T, Okada H, Iwaki S, Sobel BE, Fujii S (2011) Modulators of induction of plasminogen activator inhibitor type-1 in HepG2 cells by transforming growth factor-β. Coron Artery Dis 22(7):468–478

    PubMed  Google Scholar 

  54. Liu H, Liu A, Shi C, Li B (2016) Curcumin suppresses transforming growth factor-β1-induced cardiac fibroblast differentiation via inhibition of Smad-2 and p38 MAPK signaling pathways. Experimental and therapeutic medicine 11(3):998–1004

    CAS  PubMed  PubMed Central  Google Scholar 

  55. Zeng C, Zhong P, Zhao Y, Kanchana K, Zhang Y, Khan ZA, Chakrabarti S, Wu L, Wang J, Liang G (2015) Curcumin protects hearts from FFA-induced injury by activating Nrf2 and inactivating NF-κB both in vitro and in vivo. J Mol Cell Cardiol 79:1–12

    CAS  PubMed  Google Scholar 

  56. Soetikno V, Sari FR, Sukumaran V, Lakshmanan AP, Mito S, Harima M, Thandavarayan RA, Suzuki K, Nagata M, Takagi R (2012) Curcumin prevents diabetic cardiomyopathy in streptozotocin-induced diabetic rats: possible involvement of PKC–MAPK signaling pathway. Eur J Pharm Sci 47(3):604–614

    CAS  PubMed  Google Scholar 

  57. Guo S, Meng XW, Yang XS, Liu XF, Ou-Yang CH, Liu C (2018) Curcumin administration suppresses collagen synthesis in the hearts of rats with experimental diabetes. Acta Pharmacol Sin 39(2):195–204. https://doi.org/10.1038/aps.2017.92

    Article  PubMed  Google Scholar 

  58. Bugyei-Twum A, Advani A, Advani SL, Zhang Y, Thai K, Kelly DJ, Connelly KA (2014) High glucose induces Smad activation via the transcriptional coregulator p300 and contributes to cardiac fibrosis and hypertrophy. Cardiovasc Diabetol 13(1):89. https://doi.org/10.1186/1475-2840-13-89

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Chung CC, Kao YH, Liou LP, Chen YJ (2014) Curcumin suppress cardiac fibroblasts activities by regulating proliferation, migration, and the extracellular matrix. Acta Cardiologica Sinica 30(5):474–482

    PubMed  PubMed Central  Google Scholar 

  60. Kim YS, Kwon JS, Cho YK, Jeong MH, Cho JG, Park JC, Kang JC, Ahn Y (2012) Curcumin reduces the cardiac ischemia–reperfusion injury: involvement of the toll-like receptor 2 in cardiomyocytes. J Nutr Biochem 23(11):1514–1523

    CAS  PubMed  Google Scholar 

  61. Yu W, Wu J, Cai F, Xiang J, Zha W, Fan D, Guo S, Ming Z, Liu C (2012) Curcumin alleviates diabetic cardiomyopathy in experimental diabetic rats. PLoS One 7(12):e52013. https://doi.org/10.1371/journal.pone.0052013

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Sunagawa Y, Sono S, Katanasaka Y, Funamoto M, Hirano S, Miyazaki Y, Hojo Y, Suzuki H, Morimoto E, Marui A (2014) Optimal dose-setting study of curcumin for improvement of left ventricular systolic function after myocardial infarction in rats. J Pharmacol Sci 126(4):329–336

    CAS  PubMed  Google Scholar 

  63. Pang X-F, Zhang L-H, Bai F, Wang N-P, Garner RE, McKallip RJ, Zhao Z-Q (2015) Attenuation of myocardial fibrosis with curcumin is mediated by modulating expression of angiotensin II AT1/AT2 receptors and ACE2 in rats. Drug design, development and therapy 9:6043

    CAS  PubMed  PubMed Central  Google Scholar 

  64. Allen S, Liu YG, Scott E (2016) Engineering nanomaterials to address cell-mediated inflammation in atherosclerosis. Regen Eng Transl Med 2(1):37–50. https://doi.org/10.1007/s40883-016-0012-9

    Article  PubMed  PubMed Central  Google Scholar 

  65. Liu R, Zhang H, Yang J, Wang J, Liu J, Li C (2018) Curcumin alleviates isoproterenol-induced cardiac hypertrophy and fibrosis through inhibition of autophagy and activation of mTOR. Eur Rev Med Pharmacol Sci 22(21):7500–7508

    CAS  PubMed  Google Scholar 

  66. Ozawa H, Imaizumi A, Sumi Y, Hashimoto T, Kanai M, Makino Y, Tsuda T, Takahashi N, Kakeya H (2017) Curcumin β-D-glucuronide plays an important role to keep high levels of free-form curcumin in the blood. Biol Pharm Bull 40(9):1515–1524

    CAS  PubMed  Google Scholar 

  67. Schiborr C, Eckert GP, Rimbach G, Frank J (2010) A validated method for the quantification of curcumin in plasma and brain tissue by fast narrow-bore high-performance liquid chromatography with fluorescence detection. Anal Bioanal Chem 397(5):1917–1925

    CAS  PubMed  Google Scholar 

  68. Feng T, Wei Y, Lee RJ, Zhao L (2017) Liposomal curcumin and its application in cancer. Int J Nanomedicine 12:6027–6044. https://doi.org/10.2147/IJN.S132434

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Tsuda T (2018) Curcumin as a functional food-derived factor: degradation products, metabolites, bioactivity, and future perspectives. Food Funct 9(2):705–714

    CAS  PubMed  Google Scholar 

  70. Mirzaei H, Shakeri A, Rashidi B, Jalili A, Banikazemi Z, Sahebkar A (2017) Phytosomal curcumin: a review of pharmacokinetic, experimental and clinical studies. Biomed Pharmacother 85:102–112. https://doi.org/10.1016/j.biopha.2016.11.098

    Article  CAS  PubMed  Google Scholar 

  71. Wang Y, Zhou S, Sun W, McClung K, Pan Y, Liang G, Tan Y, Zhao Y, Liu Q, Sun J (2014) Inhibition of JNK by novel curcumin analog C66 prevents diabetic cardiomyopathy with a preservation of cardiac metallothionein expression. American Journal of Physiology-Endocrinology and Metabolism 306(11):E1239–E1247

    CAS  PubMed  Google Scholar 

  72. Li C, Miao X, Lou Y, Lu Z, Adhikari BK, Wang Y, Liu Q, Sun J, Wang Y (2018) Cardioprotective effects of the novel curcumin analogue C66 in diabetic mice is dependent on JNK 2 inactivation. J Cell Mol Med 22(12):6314–6326

    CAS  PubMed  PubMed Central  Google Scholar 

  73. Bugyei-Twum A, Abadeh A, Thai K, Zhang Y, Mitchell M, Kabir G, Connelly KA (2016) Suppression of NLRP3 Inflammasome activation ameliorates chronic kidney disease-induced cardiac fibrosis and diastolic dysfunction. Sci Rep 6:39551. https://doi.org/10.1038/srep39551

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Sunagawa Y, Morimoto T, Wada H, Takaya T, Katanasaka Y, Kawamura T, Yanagi S, Marui A, Sakata R, Shimatsu A, Kimura T, Kakeya H, Fujita M, Hasegawa K (2011) A natural p300-specific histone acetyltransferase inhibitor, curcumin, in addition to angiotensin-converting enzyme inhibitor, exerts beneficial effects on left ventricular systolic function after myocardial infarction in rats. Circ J 75(9):2151–2159. https://doi.org/10.1253/circj.CJ-10-1072

    Article  CAS  PubMed  Google Scholar 

  75. Ma J, Ma S-y, Ding C-h (2017) Curcumin reduces cardiac fibrosis by inhibiting myofibroblast differentiation and decreasing transforming growth factor β1 and matrix metalloproteinase 9/tissue inhibitor of metalloproteinase 1. Chin J Integr Med 23(5):362–369

    CAS  PubMed  Google Scholar 

Download references

Funding

Financial support was from the National Institute for Medical Research Development (NIMAD), Tehran, Iran (Grant no: 943771).

Author information

Author notes

  1. Armita Mahdavi Gorabi and Saeideh Hajighasemi contributed equally to this work.

Authors and Affiliations

  1. Research Center for Advanced Technologies in Cardiovascular Medicine, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran

    Armita Mahdavi Gorabi & Nasim Kiaie

  2. Department of Medical Biotechnology, Faculty of Paramedicine, Qazvin University of Medical Sciences, Qazvin, Iran

    Saeideh Hajighasemi

  3. Department of Medical Sciences, IRCCS San Raffaele Roma, Rome, Italy

    Giuseppe M. C. Rosano

  4. Department of Academic Diabetes, Endocrinology and Metabolism, Hull York Medical School, University of Hull, Hull, UK

    Thozhukat Sathyapalan

  5. Medical Research Centre, Sultan Qaboos University, Muscat, Oman

    Khalid Al-Rasadi

  6. Department of Biochemistry, College of Medicine and Health Sciences, Sultan Qaboos University, Muscat, Oman

    Khalid Al-Rasadi

  7. Neurogenic Inflammation Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

    Amirhossein Sahebkar

  8. Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, 9177948564, Iran

    Amirhossein Sahebkar

  9. School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

    Amirhossein Sahebkar

Authors
  1. Armita Mahdavi Gorabi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Saeideh Hajighasemi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nasim Kiaie
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Giuseppe M. C. Rosano
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Thozhukat Sathyapalan
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Khalid Al-Rasadi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Amirhossein Sahebkar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Amirhossein Sahebkar.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interests.

Ethics approval

Not applicable.

Informed consent

Not applicable.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gorabi, A.M., Hajighasemi, S., Kiaie, N. et al. Anti-fibrotic effects of curcumin and some of its analogues in the heart. Heart Fail Rev 25, 731–743 (2020). https://doi.org/10.1007/s10741-019-09854-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10741-019-09854-6

Keywords

Search

Navigation